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Abstract
Background:  Essential hypertension is a major public health concern worldwide where its
prevalence accounts for various cerebrovascular diseases. A common molecular variant of
angiotensinogen (AGT), the precursor of potent vasoactive hormone angiotensin II, has been
incriminated as a marker for genetic predisposition to essential hypertension in some ethnics. This
case-control study was designed not only to determine the association of the AGT M235T gene
variants with essential hypertension, but also its relationship to Plasma Renin Activity (PRA) in
subjects attending the Health Clinic, Kuala Lumpur, Malaysia.
Methods: The study involved 188 subjects, 101 hypertensives and 87 normotensives. Consents
were obtained from all the participated subjects. M235T gene variants were investigated using allele
specific polymerase chain reaction and PRA was determined by radioimmunoassay.
Hypertensinogenic factors such as dietary habits, physical activity, smoking and drinking habits were
assessed using a pre-tested questionnaire.
Results:  The genotype and allele distribution of the M235T variant differed significantly in
hypertensives and normotensives (χ 2 = 23.184, P < 0.001 and χ 2 = 21.482, P < 0.001, respectively).
The odds ratio for hypertension was 1.36 (95% confidence interval 1.03–1.80) for subjects with
homozygous mutated allele TT of the M235T variant compared with other genotypes or 1.98 (95%
confidence interval 1.46–2.67) for those carrying T allele compared to those carrying M allele.
Plasma Renin Activity is also significantly higher in hypertensive subjects (PRA = 3.8 ± 2.5 ngAI/ml/
hr for hypertensives, PRA = 2.6 ± 1.3 ngAI/ml/hr for normotensives, P < 0.001), but was not
significantly different between groups of genotypes (P = 0.118).
Conclusion: The M235T variant of the AGT is significantly associated with essential hypertension
whereas the genotype TT or allele T is a possible genetic marker or risk factor for hypertension in
Malaysian subjects.
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Background
High blood pressure or hypertension, 'a silent-killer' con-
dition, is now the most common chronic condition,
affecting 20–30% of the adult population. It is rapidly
becoming a major problem in developing countries,
including Malaysia. About 90–95% of hypertension
(HTN) is idiopathic and apparently primary or essential
hypertension (EH). Of the remaining 5–10%, most are
secondary to renal and adrenal diseases. EH is a multifac-
torial disorder arising from the influence of several sus-
ceptibility genes and environmental stimuli. Evidence
suggests that genes may contribute to 30% of the variation
of blood pressure. However, the number of genes
involved or the model of interaction with other genes or
environmental risk factors is unknown.
The angiotensiongen (AGT) gene regulates the expression
of angiotensinogen, a polypeptide primarily produced by
the liver. Cleavage of the angiotensinogen molecule by
renin, liberating angiotensin I, and then converted into
angiotensin II by angiotensin-converting enzyme. This
product binds to its receptor, exerting physiologic effects
on the sodium homoeostasis and vascular resistance, thus
regulates the blood pressure [1]. The plasma concentra-
tion of AGT is correlated with blood pressure [1,2]. Mice
with the AGT gene duplicated have blood pressure and
plasma AGT levels positively correlated with the number
of gene copies [3].
The human AGT gene has been cloned and sequenced [4].
Fifteen molecular variants have been identified and only
three have so far been reported to have a possible genetic
association with hypertension [5]. One variant encodes
threonine instead of methionine at position 235(T235)
[5,6], the others encode methionine instead of threonine
at position 174 [5,6] and the microsatellite (a GT-repeat
sequence, varies highly as 11 different allelic variants
among individuals) [7]. Association studies of the M235T
variant in essential hypertension have yielded conflicting
results. Some found linkage or association in Caucasian
[5-7], African-Carribean [8], Japanese [9,10] and Taiwan-
ese populations [11], while others did not [12-14]. A
molecular variant of AGT has also been reported to be
associated with preeclampsia [15].
The study addressed the question as to whether there is an
association between the AGT M235T gene variant and
essential hypertension in the Malaysian subjects since
genetic diversity exists among different ethnic popula-
tions and realizing the fact that the association in one
population could not be extrapolated to another
population.
Methods
Study subjects
Approval and permission were obtained from the ethics
committees of the Faculty of Medicine and Health Sci-
ences, Universiti Putra Malaysia, the Federal Territory
Kuala Lumpur Health Department and the Ministry of
Health, Malaysia to meet the ethics guidelines. The per-
mission allowed the study to be carried out in the Health
Clinic, Kuala Lumpur Hospital. Upon the approval, sub-
jects were recruited consecutively from patients attending
the Health Clinic from 1st October to 31st October, 2002.
The patients referred to the clinic were residents of the
Klang Valley, consisting of the Federal Territory Kuala
Lumpur and parts of the Selangor state. The subjects can
be categorized into three main ethnic groups: Malay, Chi-
nese and Indian. Hypertensive subjects were defined as
those with systolic blood pressure (SBP) of greater than or
equal to 140 mmHg, with a diastolic blood pressure
(DBP) of greater than or equal to 90 mmHg, or are cur-
rently administered at least one hypertensive medication.
Any subjects with the possibility of secondary hyperten-
sion were excluded. Hypertensive subjects whose parents
both had hypertension were considered to have a positive
family history of hypertension. Normotensive was
defined as those with a blood pressure of less than 140/90
mmHg; those with a positive family history of hyperten-
sion were excluded. Both groups with subjects under the
influence of estrogen, thyroid and cortisol hormones were
excluded. The subjects were selected by medical officers
and also approached by the field team. Informed consent
was obtained from the subjects and a total of 101 hyper-
tensives (23 males and 68 females) and 87 normotensives
(23 males and 64 females) were recruited.
Questionnaire, blood pressure and body mass index 
measurements
A three-page pre-tested questionnaire in both the Malay
and English language were developed to assess the socio-
demographic background, socio-demographic data, die-
tary habits, physical activity, smoking habits, alcohol con-
sumption and family history for hypertension. The blood
pressure (BP) was measured with the subject sitting, using
an automated sphygmomanometer (Colin Press-Mate BP-
8800C®) after at least 10 minutes of resting. Height and
weight of subjects were obtained by using the TANITA dig-
ital weighing scale and the SECA Bodymeter 208 respec-
tively. The body mass index (BMI) of subjects was
calculated as weight (kg) / height2 (m2).
Blood collection
Four to five mililitres of peripheral venous blood were col-
lected into two separate K2 EDTA vacutainer test tubes
from each subject for radioimmunoassay (RIA) and AGT
M235T variant genotyping. Overnight fasting blood sam-
ples were collected into tubes containing sodium fluoride.BMC Cardiovascular Disorders 2005, 5:7 http://www.biomedcentral.com/1471-2261/5/7
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Blood was collected using a 21-Gauge needle with a 5.0
ml syringe by a qualified phlebotomist. The collected
blood in test tubes were kept at 4°C and centrifuged at
1200 g for 15 minutes in order to separate the plasma
from whole blood. The plasma samples were frozen at -
20°C until fasting blood glucose (FBG), triglycerides
(TG), total cholesterol (TC), low-density lipoprotein
(LDL-C), high density lipoprotein (HDL-C) and its per-
centage, plasma sodium and potassium levels were deter-
mined within 3 days.
Detection of the AGT genotypes
Genomic DNA extraction was carried out using the
QIAamp® DNA Blood Mini Kit by QIAGEN®. DNA frag-
ments including the M235T variant were amplified by
allele-specific polymerase chain reaction (PCR). The AGT
M235T polymorphism was typed by the previously
described mismatch priming method with some modifi-
cations [12]. The forward primer sequence from +921 to
+941 in exon 2 of the AGT gene is 5' GAT GCG CAC AAG
GTC CTG TC 3' whereas the reverse primer sequence from
+1202 to +1224 is 5' GGT GCT GTC CAC ACT GGA CCC
C 3'. The reverse primer was designed to contain a base
substitution T→ C at the fourth last nucleotide from its 3'
end [12]. The individual PCR reaction vial contains a final
volume of 50 µl solution. One-hundred nanograms of
DNA samples was added to 14 µl of PCR master mix con-
sisting of 5.0 µl of Promega® 10X Mg Free PCR Buffer, 3.0
µl of Promega® 25 mM MgCl2, 2.5 µl of 10 pM forward
primer, 2.5 µl of 10 pM reverse primer and 1.0 ml of
Promega® 10 mM dNTP. An appropriate amount of sterile
ultrapure water (which totals up to 50 µl) was added to
each of the microfuge tube. One microlitre of 5 units/µl
Taq DNA polymerase was added to the reaction vial only
after 5 minutes of pre-denaturation process prior to per-
forming 'hot start' PCR. The 10X Mg-free PCR Buffer has a
composition of 50 mM KCl, 10 mM Tris-HCl, (pH 9.0 at
25°C) and 0.1% Triton® X-100. The PCR was performed
using the Mastercycler Gradient (Eppendorf®) for 35
cycles. The temperature for the initial denaturation of
DNA was 95°C for 1 minute, annealing at 71°C for 1
minute and extension 72°C for 1 minute and a final
extension at 72°C for 7 minutes following the last cycle.
The PCR product was subjected to PsyI (isoschizomere for
Tth111I restriction enzyme) digestion for 3 hours at 37°C
and electrophoresed on a 5.0% agarose gel with ethidium
bromide staining.
Plasma renin activity radioimmunoassay
Plasma renin activity (PRA) was determined using the
Angiotensin I [125I] RIA kit (PerkinElmer Life Sciences,
Inc.). It is a two-step protocol: the generation of Angi-
otensin I and the RIA to quantitate the amount of Angi-
otensin I generated. Plasma was incubated at 37°C, at pH
6, with protease inhibitors (EDTA, dimercaprol (BAL) and
8-hydroxyquinoline) for 1 hour to allow the generation of
angiotensin I by the endogenous renin and substrate reac-
tion. The total concentration of the Angiotensin I was
determined by radioimmunoassay. Plasma renin activity
was expressed as ng/ml/hr of angiotensin I generated. The
intra-assay coefficient of variation for this assay was 4.0 %
(n = 12) and the inter-assay coefficient of variation was
10.4% (n = 84).
Statistical analysis
The SPSS (previously known as Statistical Package for
Social Sciences) for Windows® Version 11.0 was used to
statistically analyze the data obtained. Descriptive statis-
tics were used to analyze all variable studies such as the
socio-demographic characteristics, dietary patterns, phys-
ical activity, smoking practices and alcohol consumption,
anthropometric measurements, biological parameters
and AGT genotypes of the subjects. Genotype and allele
frequencies in control and hypertensive groups were com-
pared by Chi-square (χ 2) analysis. Continuous variables
were compared between hypertensive and control groups
by Student's t test (or the Mann-Whitney U test for non-
normally distributed variables). The influence of AGT
genotype on continuous variable was investigated by one-
way ANOVA. In addition, the effect of AGT genotype on
BP was investigated with the General Linear Model
ANOVA with adjustment for age, sex, race and BMI. Mul-
tiple regression analysis was also performed with SBP or
DBP as the dependent variable and sex, age, BMI, total
cholesterol and Plasma Renin Activity and AGT genotype
(coded 0, 1, or 2 according to the number of T235 alleles)
as independent variables. P < 0.05 was considered statisti-
cally significant.
Results
Demographic data
There were a total of 188 subjects recruited in the study,
consisting of 101 hypertensives (33 males and 68
females) and 87 normotensives (23 males and 64
females). Of the 150 subjects approached, the respond-
ence rate was around 72% due to some who choose not to
participate or was excluded due to non-compliance of the
inclusion criteria. The majority of the subjects were
females. The Malays (n = 97, 51.6%) comprises more than
half of the subjects, followed by Chinese (n = 56, 29.8%)
and Indians (n = 35, 18.6%).
The hypertensive subjects ranged from 30 to 78 years old,
with a mean age of 54.7 years, while the normotensives
ranged from 25 to 78 years old, with a mean 49.3 years,
indicating that the normotensives are younger in the age
group. Sixty-three people or 62.4% of the hypertensive
subjects have a family history of hypertension while all of
the normotensives do not have a family history of hyper-
tension in order to be included in the study.BMC Cardiovascular Disorders 2005, 5:7 http://www.biomedcentral.com/1471-2261/5/7
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Genotypes and allele frequencies
Figure 1 shows the results of the PsyI digestion on PCR
products. AGT +704 T→ C missense mutation (cause
amino acid substitution of AGT M235T) created a new
restriction site with the sequence recognition: GACN
NNGT↓ C for PsyI. PsyI digested the fragment into 2 parts,
the longer fragment, 279 bp and the shorter 24 bp. How-
ever, the 5.0% agarose gel was unable to retain the shorter
fragment and it was suspected to have migrated out of the
gel. Therefore, a band at 303 bp indicates homozygous
wild-type (MM), a band at 279 bp indicates homozygous
mutated (MT) and two bands at 303 bp and 279 bp indi-
cates heterozygous mutation (TT).
According to Table 1, the prevalence of AGT M235T mis-
sense mutation in all the subjects was 17% for
homozygous mutation (21% for hypertensives and 11%
for normotensives), 34% for heterozygous mutation
(46% for hypertensives and 21% for normotensives
respectively) and 49% for homozygous wild-type (33%
for hypertensives and 68% for normotensives respec-
tively). The allele frequencies and genotype distribution
of the M235T variant were in the Hardy-Weinberg equilib-
rium in either data set for cases (χ 2 = 0.634, df = 2, p > 0.5)
and for control (χ 2 = 917.1, df = 2, p > 0.5) subjects. There
was significant difference in genotype and allele frequen-
cies between hypertensive and normotensive groups.
When the allele frequencies are categorized based on eth-
nic groups (Table 2), there were significant differences of
the prevalence of T allele between hypertensives and nor-
motensives in the Malays (45 controls and 52 cases, χ 2 =
5.0% agarose gel electrophoresis Figure 1
5.0% agarose gel electrophoresis. Lanes 1, 2 and 3 cor-
respond to RFLP pattern of homozygous mutant (TT), heter-
ozygous (MT) and homozygous wild-type (MM), respectively. 
M is a 100 bp linear DNA ladder (Promega).
Table 1: Genotype and Allele Frequencies of M235T variant of 
the AGT gene for both cases and controls.
Group Genotypes Alleles
MM TM TT M T
Hypertensives 33 46 22 112 90
Normotensives 59 18 10 136 38
Total 92 64 32 248 128
χ 2value 23.184 21.482
P* value <0.001 <0.001
Odds ratio 1.36 1.98
*Significant values were obtained through the Chi-square test.
Table 2: Frequencies of M235T variant of the AGT gene 
according to ethnic background for both cases and controls.
Group Male Female
MT M T
Hypertensives
Malay 28 14 36 26
Chinese 10 10 28 20
Indian 1 3 9 17
Total 39 27 73 63
Normotensives
Malay 25 5 48 12
Chinese 4 4 28 8
Indian 7 1 24 8
Total 36 10 100 28
χ 2value 3.836 20.828
P* value 0.140 0.001
*Significant values were obtained through the Chi-square test.BMC Cardiovascular Disorders 2005, 5:7 http://www.biomedcentral.com/1471-2261/5/7
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12.765, df = 2, p = 0.001) and Indian (20 controls and 15
cases, χ 2 = 12.519, df = 2, p = 0.001) but not the Chinese
(22 controls and 34 cases, χ 2 = 3.083, df = 2, p = 0.212).
In addition, there was significance difference between the
prevalence of the T allele of hypertensive and normoten-
sive groups in female (23 controls and 33 cases, χ 2 =
20.828, df = 2, p = 0.001) but no significant differences
between groups in male (64 controls and 68 cases, χ 2 =
3.836, df = 2, p = 0.140).
PRA levels
According to Table 3, PRA was significantly higher (p <
0.001) in hypertensive subjects (n = 101, 3.8 ± 2.5 ngAI/
ml/hr) compared to normotensive subjects (n = 87, 2.6 ±
1.3 ngAI/ml/hr,). However, the PRA was higher in hyper-
tensives group among all the genotypes but not signifi-
cantly different between genotypes classes (p = 0.687,
hypertensives and p = 0.252, normotensives) as shown in
Figure 2.
The means of the PRA were not significantly different
between female and male among hypertensives and nor-
motensives. One way ANOVA also showed that there was
no significant difference of PRA between age groups in
both hypertensives and normotensives (p = 0.611 and p =
0.119, respectively).
BP variations
Table 4 shows BP and other variables according to AGT
genotypes in hypertensive and normotensive data sets.
There was no significant difference between genotype
classes for both normotensives and hypertensives for
unadjusted BP and any other measured variable. After
adjustment was done to BP, SBP was significantly differ-
ent between genotype classes in hypertensives. BP was sig-
nificantly lowered (p < 0.001) in normotensives (124.0 ±
17.6 / 74.1 ± 11.2 mmHg) as compared to hypertensives
(150.3 ± 21.9 / 84.3 ± 12.6 mmHg).
By multiple regression analysis, age was only the predictor
of SBP in the hypertensive group (P < 0.001) but not AGT
genotype (R2 = 0.147, p = 0.019 for SBP, R2 = 0.064, p =
0.380 for DBP). BMI was the predictor for both SBP and
DBP in the control group (P = 0.037 for SBP, P < 0.001 for
DBP). Meanwhile, age and sex (P < 0.001 and 0.027
respectively) were the predictors for SBP in the control
group (R2 = 0.376, p < 0.001 for SBP, R2 = 0.104, p = 0.172
for DBP). Sex, age, BMI, total cholesterol and Plasma
Renin Activity and AGT genotype were all not predictors
for SBP and DBP in hypertensive subjects (R2 = 0.147, p <
0.019 for SBP, R2 = 0.064, p = 0.380 for DBP).
Associated risk factors
Although normotensive subjects were younger, there was
no significant difference between the two groups with
respect to vegetarian practices, exercise, smoking practices,
alcohol drinking, glucose level (6.2 ± 2.7 mmol/L for
cases and 6.7 ± 3.3 mmol/L for control, p = 0.198) TG (1.7
± 0.9 mmol/L for cases and 1.6 ± 1.1 mmol/L for control,
p = 0.558), TTLC (5.5 ± 1.1 mmol/L for cases and 5.3 ± 1.1
Table 3: Plasma renin activity (PRA) levels according to genotypes and genders in both the cases and controls. Values are expressed in 
ngAI/ml/hr ± standard deviation. Values in parentheses represent the number of subjects.
Genotypes Normotensives Hypertensives Total p*
Male Female Male Female Male Female
MM 2.77 ± 1.69 (15) 2.54 ± 1.24 (44) 3.68 ± 2.14 (13) 3.29 ± 2.97 (20) 3.19 ± 1.93 (28) 2.77 ± 1.96 (64) 0.118a
MT 3.16 ± 1.29 (6) 2.65 ± 1.24 (12) 3.88 ± 2.90 (13) 3.95 ± 2.51 (33) 3.65 ± 2.49 (19) 3.61 ± 2.31 (45) 0.292e
TT 1.47 ± 1.38 (2) 2.08 ± 1.28 (8) 2.56 ± 1.47 (7) 4.45 ± 2.34 (15) 2.32 ± 1.45 (9) 3.63 ± 2.31 (23) 0.129f
Total 2.76 ± 1.57 (23) 2.50 ± 1.24 (64) 3.52 ± 2.35 (33) 3.87 ± 2.62 (68) 3.21 ± 2.09 (56) 3.21 ± 2.17 (132)
2.57 ± 1.32 (87) 3.75 ± 2.53 (101) 3.21 ± 2.14 (188)
p§ 0.434b 0.521c 0.997d
<0.001g
*Significant values were obtained through one-way ANOVA between agroups of genotypes, eamong males between groups of genotypes and famong 
females between groups of genotypes.
§Significant values were obtained through Student T-test between bnormotensive males and females, chypertensive males and females, dmales and 
females, and gnormotensive and hypertensive subjects.BMC Cardiovascular Disorders 2005, 5:7 http://www.biomedcentral.com/1471-2261/5/7
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Plasma renin activity (PRA), systolic blood pressure (SBP) and diastolic blood pressure (DBP) for normotensive and hyperten- sive subjects as grouped according to AGT M235T genotypes Figure 2
Plasma renin activity (PRA), systolic blood pressure (SBP) and diastolic blood pressure (DBP) for normoten-
sive and hypertensive subjects as grouped according to AGT M235T genotypes. The values were expressed as 
mean (as indicated by the red dots) whereas the bars represent the 95.0% confidence interval of standard deviations. N repre-
sents the number of subjects. MM, MT and TT correspond to homozygous wild-type, heterozygous and homozygous mutant, 
respectively.BMC Cardiovascular Disorders 2005, 5:7 http://www.biomedcentral.com/1471-2261/5/7
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mmol/L for control, p = 0.084), LDLC (3.5 ± 1.0 mmol/L
for cases and 3.3 ± 0.9 mmol/L for control, p = 0.162),
HDLC (1.3 ± 0.5 mmol/L for cases and 1.3 ± 0.3 mmol/L
for control, p  = 0.875) and plasma sodium (139 ± 5
mmol/L for cases and 139 ± 3 mmol/L for control, p =
0.285) and potassium levels (4.0 ± 0.5 mmol/L for cases
and 4.0 ± 0.4 mmol/L for control, p = 0.921).
However, using the Mann-Whitney U test shows that cof-
fee consumption habit (69 cases and 71 controls, p  =
0.038) whereas Student's T-test shows that BMI (28.8 ±
5.2 kg/m2 for cases and 25.8 ± 3.6 kg/m2 for control, p =
0.001) were lower in control subjects. The Pearson's Cor-
relation test showed no correlation between exercise fre-
quency and PRA in both hypertensives (p = 0.369, r = -
0.098) and normotensives (p = 0.088, r = -0.170). No
association was observed between years of smoking and
years of drinking habits with PRA in both hypertensives (p
= 0.994, r = -0.007 and p = 0.691, r = 0.040 respectively)
and normotensives (p = 0.223, r = -0.123 and p = 0.174, r
= -0.147 respectively).
Discussion
In this study, it was found that the M235T polymorphism
of the AGT gene is associated with essential hypertension.
The relative risks for hypertension are 1.36 for subjects
carrying the TT phenotype and 1.98 for those having allele
T of the M235T variants. These results saw some
agreement with some studies, but not with others. Jeune-
maitre and associates [5] were the first to report the link-
age of the molecular variants M235T with hypertension in
the Whites/Caucasians. Subsequent studies among the
Whites/Caucasians supported the former finding [16,17]
while others did not [7,18,19]. The association studies in
the Africans /African-Americans mostly found a negative
association [8,13,20], but the T allele is associated with
increased plasma AGT [13,20]. Studies on other Asian
populations like the three studies in the Japanese
population, found a positive association. [9,10,21] but
not in others [14,22]. The Chinese [23] and the Taiwanese
[11] population reported a positive association.
The frequency of the T235 variant among hypertensives
this study, which was 0.45, is similar to the French cohort
by the initial report by Jeunemaitre and associates [5].
Subsequent studies of the White populations reported fre-
quencies of T235 allele in control groups of approximate
0.40, with the range from 0.31 [24] to 0.49 [7]. The fre-
quency of T235 allele among Africans and African Ameri-
cans is much higher than in whites, with the frequency as
high as 0.92 [25]. Among the Japanese, the frequency is
similarly high, around 0.75 [21]. Our study showed a
higher Odds Ratio (O.R.) of 1.98 (95% CI, 1.46–2.67)
compared to a recent meta-analysis [26] of 12 studies in
the Whites which indicated that T235 is associated with a
20% increase risk of hypertension (O.R. = 1.22, 95% CI,
1.10–1.29).
In this study, the significantly higher prevalence of T allele
in hypertensive females is in agreement with the study by
Jeunemaitre et al., [5] which reported that the T allele was
significantly more prevalent among female hypertensives
(0.51) than in controls (0.37) (χ 2 = 16.9, p < 0.001). In
contrast, Freire and associates [27], found that the AGT
M235T homozygous mutation genotype was significantly
higher in male compared to female, and Pereira et al. [28]
reported that no association between gender and T allele
in a cross-sectional study involving 647 females and 776
Table 4: Blood pressure and other variables according to AGT genotypes in normotensive and hypertensive subjects. Values are 
expressed as mean. Values in parentheses represent standard deviation unless stated otherwise.
Variables Hypertensives Normotensives
M/M (n = 33) M/T (n = 46) T/T (n = 22) p* M/M (n = 59) M/T (n = 18) T/T (n = 10) p*
Age 55.5 (8.9) 55.1 (9.0) 52.7 (9.0) 0.498 48.2 (10.2) 53.7 (9.0) 48.5 (12.4) 0.136
SBP, mmHg 151.5 (16.2) 150.8 (25.9) 147.6 (20.6) 0.795 122.0 (18.0) 129.1 (15.8) 126.9 (17.8) 0.283
Adjusted SBP, mmHg 150.9 (3.7) 149.6 (3.1) 150.8 (4.6) 0.014ψ 122.6 (1.9) 126.5 (3.5) 128.1 (4.5) 0.123ψ
DBP, mmHg 81.7 (14.7) 85.4 (12.3) 85.9 (9.3) 0.352 74.4 (12.0) 73.7 (11.4) 73.0 (4.6) 0.930
Adjusted DBP, mmHg 81.6 (2.2) 85.1 (1.9) 86.7 (2.8) 0.382ψ 74.4 (1.4) 73.0 (2.6) 73.8 (3.4) 0.106ψ
BMI 27.9 (4.7) 30.0 (4.9) 27.6 (6.3) 0.098 25.9 (3.4) 25.7 (3.3) 25.3 (4.9) 0.860
*Significant values were obtained through one-way ANOVA unless stated otherwise.
ψ Significant values were obtained through ANOVA using a general linear model with adjustment for age, sex, race and BMI.BMC Cardiovascular Disorders 2005, 5:7 http://www.biomedcentral.com/1471-2261/5/7
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males. However, both of the studies were not confined to
essential hypertensive patients.
Although the T235 allele is associated with increased
plasma AGT in Blacks [20,25], the measurement of
plasma AGT was not conducted in this study. However,
the Plasma Renin Activity (PRA) test, which is the indica-
tor of hyperaldosteronism, was carried out. Decreased
PRA indicates primary hyperaldosteronism (adrenal-ori-
gin), while increased PRA indicates secondary hyperaldos-
teronism, an extra-adrenal cause. The concentration of
AGT in blood is rate-limiting, and a change in its concen-
tration can affect PRA [29]. The normal circulation level of
AGT is close to Km, which means that a rise in plasma
AGT could cause close to linear increase in the rate of angi-
otensin formation [29]. However, in vivo, an increase in
plasma AGT will not increase the rate of angiotensin pro-
duction, since the secretion of renin normally has a feed-
back relationship with angiotensin II so as to maintain a
physiologically appropriate rate of formation of
angiotensin II. [30] Exceptions of this condition are in
individuals under estrogen influence [31] and in Cush-
ing's syndrome [32]. An exclusively AGT-dependent
hypertension is thus theoretically impossible, although
two exceptional cases of hypertension associated with
hepatic cell tumors producing large amounts of AGT have
been reported [33,34]. Thus, this justifies that the meas-
urement of PRA being done, instead of plasma AGT levels.
PRA has an advantage of estimating the extent of aldoster-
one in response to the activation of the Renin-Angiotensin
System (RAS). In this study, the PRA was significantly
higher in hypertensive subjects (P < 0.0001), thus suggest-
ing that the over activity of the RAS as a whole, thus con-
tributing to hypertension. However, the PRA was not
significantly different between groups of genotypes (P =
0.118).
There are several possible reasons for the discrepancies
found between previous studies and this study. It might
be due to ethnic differences due to the heterogenous pop-
ulation or sampling bias. The background of the study
subjects recruited from a hypertensive clinic in this study
might differ from that of subjects selected from the gen-
eral population. Racial differences, including diverse
social and cultural factors may have contributed to the dif-
ferent results. Discrepancies may also be related to differ-
ent methodologies and study designs used.
The mechanism by which the molecular variant M235T of
the AGT gene is related to hypertension is poorly under-
stood. The AGT 235T variant has been found to be in com-
plete linkage disequilibrium with a guanine-to-adenosine
transition at -6 bp upstream of the initiation site of tran-
scription [35]. In vitro tests of promoter activity and DNA-
binding studies with nuclear proteins show that this
nucleotide substitution affects the basal transcription rate
of this gene in various cell lines, thereby the AGT T235
variant and increased plasma AGT levels [5] and hence
might contribute to the elevation of blood pressure.
There were some limitations in this study. First, the nor-
motensive subjects were relatively young compared with
the hypertensives, although a 5-year difference in age
might not have caused significant blood pressure varia-
tion. Secondly, the case-control design used to investigate
the influence of the AGT 235T variant is known to be
prone to selection bias and confounding especially when
applied to the investigation of complex genetic traits, such
as BP. The population studied was also not homogenous,
as Malaysians consists of different ethnic groups, with dif-
ferent genetic make-up. While a positive association does
not necessarily prove a causal relationship, it can provide
useful information regarding the clinical importance of a
genetic marker. Therefore, linkage and association studies
are complementary, each providing a different type of
information [36].
The mechanism by which the M235T variant contributes
to the pathogenesis of hypertension needs to be eluci-
dated further. It is also not possible to determine at the
present whether the observed molecular variants of the
AGT gene directly affect angiotensinogen function or
whether they are markers of functional variants that have
not yet been detected. If indeed the T235 variant directly
affects plasma angiotensinogen concentration, it will be
necessary to look for a possible difference in clearance rate
of Km for renin between the two angiotensinogen iso-
forms. The response to antihypertensive agents, especially
those blocking the RAS will have to be evaluated in
patients classified according to their AGT genotype (phar-
macogenomics). With the establishment of the associa-
tion of the M235T variant with EH, further association
studies of other cardiovascular diseases and diabetes
involving this variant or other candidate genes involving
the RAS system can be done. Hence, further genotyping of
the Malaysian population could predict the risk of getting
hypertension or other related cardiovascular disease.
Conclusion
In this study, the T235 variant of the AGT gene is associ-
ated with essential hypertension in Malaysian subjects.
The T235 variant is a risk factor or possibly a potential
genetics marker for hypertension. Plasma renin activity is
also significantly higher in hypertensive subjects but was
not significantly different between groups of genotypes.
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